Kura Oncology
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2014-01-01
- Employees
- 142
- Market Cap
- $1.5B
- Website
- http://www.kuraoncology.com
- Introduction
Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in San Diego, CA.
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
- Conditions
- Acute Myeloid Leukemia (AML)
- Interventions
- First Posted Date
- 2025-06-05
- Last Posted Date
- 2025-06-05
- Lead Sponsor
- Kura Oncology, Inc.
- Target Recruit Count
- 1300
- Registration Number
- NCT07007312
A Study of Ziftomenib, an Oral Menin Inhibitor, in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
- Conditions
- Gastrointestinal Stromal Tumor (GIST)Gastrointestinal Stromal Tumor (GIST) of the Gastrointestinal TractGastrointestinal Stromal CancerGastrointestinal Stromal NeoplasmGastrointestinal Stromal Tumor, MalignantGastrointestinal Stromal Cell Tumors
- Interventions
- First Posted Date
- 2024-10-23
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Kura Oncology, Inc.
- Target Recruit Count
- 157
- Registration Number
- NCT06655246
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
- Conditions
- Solid Tumors With HRAS AlterationsNon Small Cell Lung Cancer (NSCLC)Colorectal Cancer (CRC)Pancreatic Ductal Adenocarcinoma (PDAC)Clear Cell Renal Cell Carcinoma (ccRCC)Renal Cell Carcinoma (Kidney Cancer)
- Interventions
- First Posted Date
- 2023-09-07
- Last Posted Date
- 2025-06-13
- Lead Sponsor
- Kura Oncology, Inc.
- Target Recruit Count
- 270
- Registration Number
- NCT06026410
- Locations
- 🇺🇸
Henry Ford Health System, Detroit, Michigan, United States
🇺🇸UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
🇺🇸UT Southwestern Simmons Cancer Center, Dallas, Texas, United States
A Study to Investigate the Safety and Tolerability of Ziftomenib Combinations in Patients with Relapsed/Refractory Acute Myeloid Leukemia
- Conditions
- Relapsed and/or refractory Acute Myeloid Leukemia
- Interventions
- Biological: Granulocyte colony-stimulating factor
- First Posted Date
- 2024-08-22
- Last Posted Date
- 2025-06-17
- Lead Sponsor
- Kura Oncology Inc.
- Target Recruit Count
- 30
- Registration Number
- 2023-510288-37-00
- Locations
- 🇩🇪
Medizinische Hochschule Hannover, Hanover, Germany
🇮🇹Azienda Unita Sanitaria Locale Della Romagna, Ravenna, Italy
🇮🇹Azienda Ospedaliero-Universitaria Di Bologna IRCCS Istituto Di Ricerca E Di Cura A Carattere Scientifico, Bologna, Italy
Expanded Access to Ziftomenib
- Conditions
- Acute Lymphoblastic Leukemia, With Appropriate MutationsAcute Myeloid Leukemia, With NPM1 Mutations
- First Posted Date
- 2023-02-22
- Last Posted Date
- 2025-06-04
- Lead Sponsor
- Kura Oncology, Inc.
- Registration Number
- NCT05738538
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, or 7+3 in Patients With AML
- Conditions
- Acute Myeloid LeukemiaMixed Lineage Acute LeukemiaMixed Lineage Leukemia Gene MutationMixed Phenotype Acute LeukemiaRefractory AMLAML With Mutated NPM1Acute Myeloid Leukemia RecurrentAcute Myeloid Leukemia, in RelapseNPM1 MutationKMT2Ar
- Interventions
- First Posted Date
- 2023-02-21
- Last Posted Date
- 2025-06-05
- Lead Sponsor
- Kura Oncology, Inc.
- Target Recruit Count
- 212
- Registration Number
- NCT05735184
- Locations
- 🇺🇸
Mayo Clinic - Phoenix, Phoenix, Arizona, United States
🇺🇸Moores UC San Diego Cancer Center, La Jolla, California, United States
🇺🇸USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
Tipifarnib and Osimertinib in EGFR-mutated Non-Small Cell Lung Cancer
- First Posted Date
- 2023-01-20
- Last Posted Date
- 2023-03-06
- Lead Sponsor
- Kura Oncology, Inc.
- Registration Number
- NCT05693090
- Locations
- 🇺🇸
Providence Medical Group, Santa Rosa, California, United States
🇺🇸The Valley Hospital, Ridgewood, New Jersey, United States
Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
- First Posted Date
- 2021-08-10
- Last Posted Date
- 2025-04-06
- Lead Sponsor
- Kura Oncology, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT04997902
- Locations
- 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸Lake Nona DDU (Florida Cancer Specialists), Orlando, Florida, United States
🇺🇸University of Maryland School of Medicine (Marlene and Stewart Greenebaum Comprehensive Cancer Center), Baltimore, Maryland, United States
Cardiovascular Safety Study of Tipifarnib in Patients With Advanced Solid Malignancies
- First Posted Date
- 2021-04-29
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Kura Oncology, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT04865159
- Locations
- 🇺🇸
Gabrail Cancer Center Research, Canton, Ohio, United States
🇺🇸NEXT Oncology, San Antonio, Texas, United States
Expanded Access to Tipifarnib
- Conditions
- HRAS Mutations or Peripheral T Cell Lymphoma (PTCL)
- First Posted Date
- 2021-03-22
- Last Posted Date
- 2025-06-04
- Lead Sponsor
- Kura Oncology, Inc.
- Registration Number
- NCT04809233